How to Produce an Investor-Grade Biotech Valuation Pack

Credibility comes before precision

A biotech valuation pack becomes credible when an informed reader can see what had to be true for the number to exist.

That distinction matters in biotech more than in many other industries. Probability of success, timing, regulatory path, competitive position, pricing, access, and financing needs are all uncertain. A spreadsheet can hide weak thinking very effectively.

Where teams usually go wrong

The first mistake is treating valuation as a finance-only exercise. In biotech, the model is only as good as the scientific, clinical, and competitive picture behind it.

The second mistake is burying major assumptions in tabs rather than surfacing them in the argument.

The third mistake is underplaying scenario structure. In high-uncertainty assets, the midpoint tells you much less than people often pretend.

Step 1: build the asset case before the model

A useful valuation pack should state clearly:

• the asset and target thesis
• the patient and commercial logic
• the current development stage
• the next value-inflecting milestone
• the competitive context that shapes upside and downside

This gives the model an operating frame instead of making it a detached spreadsheet exercise.

Step 2: surface the assumptions explicitly

A serious pack should show the major assumptions in plain language.

• What probability of technical and regulatory success is being assumed?
• What development timeline is implied?
• What pricing and uptake logic drive revenue?
• Which cost or financing burdens matter most?
• Which assumptions are internal beliefs and which are grounded in precedent?

This is where the pack becomes honest.

Step 3: structure the model in layers

Base case

What is the value if the current thesis broadly holds?

Sensitivity layer

Which variables move the valuation most?

Scenario layer

What happens if timing slips, the readout is mixed, the market is smaller, or differentiation is stronger than expected?

An investor-grade pack needs all three.

Step 4: make the number interpretable

Visuals are there for interpretation.

A good pack uses a small number of artifacts to show what is really doing the work: waterfall views, sensitivity charts, timeline paths, scenario matrices. These artifacts force the team to expose value drivers and allow the reader to challenge them intelligently.

Step 5: end with an investment conclusion

A good valuation pack should answer:

1. What is the fair range now?
2. Which assumptions matter most?
3. What breaks the view fastest?
4. What event would improve it most?

Without that layer, the output is still modeling rather than investor-grade interpretation.

The best packs make disagreement easier

This is a subtle but important point. A strong valuation pack gives sophisticated readers somewhere precise to disagree.

An investor may accept the asset thesis but reject the timing. Another may accept the timing but challenge pricing. A board member may accept the model structure but think the company is underestimating competitive density. Good valuation work helps those disagreements become explicit. Weak valuation work hides them inside one smooth number.

How ARiDA helps

ARiDA's valuation work is tiered for the same reason biotech finance work is tiered in real life. Essential rNPV Valuation is the single-asset baseline. Fundraise Valuation Pack adds dilution and term-sheet logic. Professional Portfolio Valuation handles multi-asset diligence. Enterprise Valuation & Board Risk Pack adds real-options analysis, Bayesian probability updates, portfolio optimization, and a board dossier.

Those workflows are built around a valuation specialist working alongside web research, literature, and database work, with a coding specialist generating the supporting visuals and scenario artifacts. At the higher tiers, the workflow produces platform diagnostics, real-options outputs, portfolio rNPV views, and board-deck material. The practical advantage is that the upstream evidence stays connected to the model. The memo can still trace back to the assumptions, and the assumptions can still trace back to the evidence that shaped them.

The investor test

In biotech, a valuation pack is strongest when it makes uncertainty visible rather than trying to smooth it away.

That requires a workflow where the narrative, the assumptions, the model artifacts, and the supporting evidence remain connected.